University of Texas's MD Anderson Cancer Center: Androgen Receptor Signaling Contributes to Targeted Therapy Resistance in Melanoma
June 16, 2022
June 16, 2022
HOUSTON, Texas, June 16 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on June 15, 2022:
* * *
Inhibiting androgen receptor improved treatment response in preclinical study
* * *
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from The University of Texas MD Anderson Cancer Center showed in a study publish . . .
* * *
Inhibiting androgen receptor improved treatment response in preclinical study
* * *
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from The University of Texas MD Anderson Cancer Center showed in a study publish . . .